All In Biotech

NDA 214787 · Gilead Sciences INC

Veklury

Remdesivir · Intravenous · SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Oct 22, 2020

Approved uses

5

Original approval plus efficacy supplements

Registered trials

104

51 Phase 3, 16 recruiting

FAERS reports

13,295

11,170 serious, 3,305 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. VEKLURY is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. ( 1 )

Mechanism: Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VEKLURY · REMDESIVIR 100MG/20ML (5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • VEKLURY · REMDESIVIR 100MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Remdesivir" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,245
  • alanine aminotransferase increased935
  • covid-19919
  • drug ineffective768
  • death762
  • bradycardia652
  • acute kidney injury630
  • aspartate aminotransferase increased629
  • respiratory failure552
  • covid-19 pneumonia505
  • liver function test increased422
  • condition aggravated396

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20194
20204,479
20212,859
20222,598
20231,647
20241,011
2025536
2026160

Recalls

2 FDA enforcement reports for this application.

  • Sep 19, 2024 · Class I · Terminated

    Presence of Particulate Matter: Presence of glass particle.

  • Dec 3, 2021 · Class I · Terminated

    Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Veklury (Remdesivir)

2024 spending

$381K

Beneficiaries

164

292 claims

Per beneficiary

$2,324

$208.57 per unit

View as table
YearSpending
2020$0
2021$0
2022$253,542
2023$582,565
2024$381,126

Part B: Veklury (Remdesivir) · HCPCS J0248

2024 spending

$14.6M

Beneficiaries

7,399

13,477 claims

Per beneficiary

$1,978

2024 ASP limit $6.21 per unit

View as table
YearSpending
2020$0
2021$121,749
2022$28,042,110
2023$22,660,480
2024$14,633,667

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 232 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.